Telix Pharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent 2023-12-04 13:00
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS 2023-11-30 04:15
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam® 2023-11-14 06:33
Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery 2023-11-13 16:27
First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591 2023-11-13 07:38
Telix to Present at Jefferies London Healthcare Conference 2023 2023-11-09 04:51
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region 2023-11-08 13:00
ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability 2023-10-19 06:01
Telix reports fourth consecutive quarter of positive operating cash flow 2023-10-18 15:42
HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South 2023-09-27 12:00
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM 2023-09-06 14:18
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company 2023-08-23 17:40
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients 2023-08-11 11:14
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients 2023-08-11 07:18
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma 2023-08-08 06:24
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow 2023-07-19 16:14
First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib 2023-07-19 05:00
New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC 2023-06-27 03:51
Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI 2023-06-22 19:00
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical 2023-06-21 17:32
1 2 3 4 5 7